Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women

ng-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women Review (4096) Total Article Views Authors: Sharath Gangadhara, Gianfilippo Bertelli Published Date April 2009 Volume 2009:5 Pages 291 - 300 DOI: http://dx.doi.org/10.2147/TCRM.S3856 Sharath Gangadhara, Gianfilippo Bertelli South West Wales Cancer Institute, Singleton Hospital, Swansea, UK Abstract: For more than 20 years, tamoxifen has been the gold standard for the adjuvant treatment of postmenopausal women with hormone-responsive early breast cancer. However, recent randomized trials have shown efficacy and tolerability benefits with the third-generation aromatase inhibitor anastrozole, resulting in an increased use of this agent in the adjuvant setting. Data on anastrozole’s long-term efficacy and tolerability are therefore of interest in clinical practice and will be reviewed here, especially in the light of the 100-month analysis of the ATAC (Anastrozole, Tamoxifen Alone or in Combination) trial.